Subscribe
shutterstock_1843221310_maxshot_pl
MAXSHOT.PL / Shutterstock.com
9 December 2021GenericsAlex Baldwin

GSK responds to Teva’s ‘skinny’ label rehearing petition

Following a substantial push from generics companies to reverse the GSK v Teva “skinny” label ruling, GlaxoSmithKilne (GSK) has added its response to the petition to rehear the case yet again.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
GSK scientist pleads guilty to trade secret theft
4 January 2022   Former GlaxoGlaxoSmithKline scientists conspired to steal trade secrets to benefit the Chinese firm, Renopharma, according to the US Department of Justice.
Americas
GSK to buy Sierra Oncology for $1.9bn
14 April 2022   GlaxoSmithKline has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
GSK scientist pleads guilty to trade secret theft
4 January 2022   Former GlaxoGlaxoSmithKline scientists conspired to steal trade secrets to benefit the Chinese firm, Renopharma, according to the US Department of Justice.
Americas
GSK to buy Sierra Oncology for $1.9bn
14 April 2022   GlaxoSmithKline has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.

More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
GSK scientist pleads guilty to trade secret theft
4 January 2022   Former GlaxoGlaxoSmithKline scientists conspired to steal trade secrets to benefit the Chinese firm, Renopharma, according to the US Department of Justice.
Americas
GSK to buy Sierra Oncology for $1.9bn
14 April 2022   GlaxoSmithKline has agreed to acquire California-based biopharma company Sierra Oncology for $1.9 billion, in a move that bolsters the UK company’s cancer business.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent